BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18384181)

  • 1. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft.
    Lee SC; Huang MQ; Nelson DS; Pickup S; Wehrli S; Adegbola O; Poptani H; Delikatny EJ; Glickson JD
    NMR Biomed; 2008 Aug; 21(7):723-33. PubMed ID: 18384181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
    Huang MQ; Nelson DS; Pickup S; Qiao H; Delikatny EJ; Poptani H; Glickson JD
    Acad Radiol; 2007 Dec; 14(12):1531-9. PubMed ID: 18035282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP.
    Lee SC; Delikatny EJ; Poptani H; Pickup S; Glickson JD
    NMR Biomed; 2009 Apr; 22(3):259-65. PubMed ID: 19040203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR metabolic and physiological markers of therapeutic response.
    Lee SC; Poptani H; Delikatny EJ; Pickup S; Nelson DS; Schuster SJ; Nasta SD; Svoboda J; Goldstein SC; Wallace SG; Loevner LA; Mellon EA; Reddy R; Glickson JD
    Adv Exp Med Biol; 2011; 701():129-35. PubMed ID: 21445779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
    Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
    Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging.
    Lee SC; Poptani H; Pickup S; Jenkins WT; Kim S; Koch CJ; Delikatny EJ; Glickson JD
    NMR Biomed; 2010 Jul; 23(6):624-32. PubMed ID: 20661875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
    Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM
    Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.
    Levi E; Zhang L; Aboukameel A; Rishi S; Mohammad RM; Polin L; Hatfield JS; Rishi AK
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1401-13. PubMed ID: 20809119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice.
    Xu HN; Mir TA; Lee SC; Feng M; Farhad N; Choe R; Glickson JD; Li LZ
    Adv Exp Med Biol; 2013; 789():243-249. PubMed ID: 23852501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
    Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
    Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI.
    Huang MQ; Pickup S; Nelson DS; Qiao H; Xu HN; Li LZ; Zhou R; Delikatny EJ; Poptani H; Glickson JD
    NMR Biomed; 2008 Nov; 21(10):1021-9. PubMed ID: 18988250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactate imaging with Hadamard-encoded slice-selective multiple quantum coherence chemical-shift imaging.
    Pickup S; Lee SC; Mancuso A; Glickson JD
    Magn Reson Med; 2008 Aug; 60(2):299-305. PubMed ID: 18666110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 19. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
    Hong J; Woo HS; Kim H; Ahn HK; Sym SJ; Park J; Ahn JY; Cho EK; Shin DB; Lee JH
    Cancer Sci; 2014 Dec; 105(12):1569-75. PubMed ID: 25263825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.